Ausgabe 3/2019
Inhalt (26 Artikel)
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
Marina Elena Cazzaniga, Romano Danesi, Corrado Girmenia, Pietro Invernizzi, Alessandra Elvevi, Massimo Uguccioni, Laura Amaducci, Francesco Atzori, Livio Blasi, Chiara Butti, Elena Collovà, Enrico De Conciliis, Alessandra Fabi, Antonio Febbraro, Ornella Garrone, Lorenzo Gianni, Francesco Giotta, Nicla La Verde, Andrea Michelotti, Raffaella Palumbo, Ida Paris, Mirco Pistelli, Laura Pizzuti, Daniela Rubino, Maria Rosaria Valerio, Fable Zustovich
Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer
Michael Patrick Lux, Sarah Böhme, Stephanie Hücherig, Ulli Jeratsch, Niclas Kürschner, Diana Lüftner
De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis
Arif Ali Awan, Brian Hutton, John Hilton, Sasha Mazzarello, Catherine Van Poznak, Lisa Vandermeer, Brianne Bota, Carol Stober, Marta Sienkiewicz, Dean Fergusson, Risa Shorr, Mark Clemons
Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis
Motahare Pilevarzadeh, Mehrbanoo Amirshahi, Roghaiyeh Afsargharehbagh, Hosein Rafiemanesh, Seyed-Mehdi Hashemi, Abbas Balouchi
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis
John Silberholz, Dimitris Bertsimas, Linda Vahdat
Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer
Evan N. Cohen, Tamer M. Fouad, Bang-Ning Lee, Banu K. Arun, Diane Liu, Sanda Tin, Angelica M. Gutierrez Barrera, Toshihide Miura, Iwao Kiyokawa, Jun Yamashita, Ricardo H. Alvarez, Vicente Valero, Wendy A. Woodward, Yu Shen, Naoto T. Ueno, Massimo Cristofanilli, James M. Reuben
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
Carsten Denkert, Jan Budczies, Meredith M. Regan, Sibylle Loibl, Patrizia Dell’Orto, Gunter von Minckwitz, Mauro G. Mastropasqua, Christine Solbach, Beat Thürlimann, Keyur Mehta, Jens-Uwe Blohmer, Marco Colleoni, Volkmar Müller, Frederick Klauschen, Beyhan Ataseven, Knut Engels, Roswitha Kammler, Berit M. Pfitzner, Manfred Dietel, Peter A. Fasching, Giuseppe Viale
T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer
Hitomi Mori, Makoto Kubo, Masaya Kai, Mai Yamada, Kanako Kurata, Hitomi Kawaji, Kazuhisa Kaneshiro, Tomofumi Osako, Reiki Nishimura, Nobuyuki Arima, Masayuki Okido, Junji Kishimoto, Yoshinao Oda, Masafumi Nakamura
Efficacy of a web-based women’s health survivorship care plan for young breast cancer survivors: a randomized controlled trial
H. Irene Su, Shaylyn Stark, Brian Kwan, Sarah Boles, Diana Chingos, Jennifer Ehren, Jessica R. Gorman, Michael Krychman, Sally A. D. Romero, Jun J. Mao, John P. Pierce, Loki Natarajan
Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy
Hee Jun Choi, Jai Min Ryu, Isaac Kim, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Jeong Eon Lee, Se Kyung Lee
Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival
B. M. Aarts, E. G. Klompenhouwer, R. C. Dresen, A. Laenen, R. G. H. Beets-Tan, K. Punie, P. Neven, H. Wildiers, G. Maleux
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)
Christel Fontaine, Vincent Renard, Heidi Van den Bulk, Peter Vuylsteke, Philip Glorieux, Catherine Dopchie, Lore Decoster, Leen Vanacker, Evandro de Azambuja, Jacques De Greve, Ahmad Awada, Hans Wildiers
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy
Jennifer Y. Sheng, Amanda L. Blackford, Aditya Bardia, Raghunandan Venkat, Gedge Rosson, Jon Giles, Daniel F. Hayes, Stacie C. Jeter, Zhe Zhang, Jill Hayden, Anne Nguyen, Anna Maria Storniolo, Karineh Tarpinian, Norah Lynn Henry, Vered Stearns
The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
Noriko Sagawa, Shinji Ohno, Takahiro Hiratsuka, Naoto Kondo, Hiroji Iwata, Hiroko Bando, Tetsuji Ohyama, Mayumi Ishida, Yohei Kono, Kentaro Nakajima, Shinichiro Empuku, Setsuko Nishikawa, Yoshiko Irie, Masafumi Inomata, Seigo Kitano
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study
Shinji Ohno, Hirofumi Mukai, Kazutaka Narui, Yasuo Hozumi, Yasuo Miyoshi, Hiroshi Yoshino, Hiroyoshi Doihara, Akihiko Suto, Motoshi Tamura, Takashi Morimoto, Hisamitsu Zaha, Takashi Chishima, Reiki Nishimura, Takashi Ishikawa, Yukari Uemura, Yasuo Ohashi
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer
Thomas Decker, Norbert Marschner, Axel Muendlein, Anja Welt, Volker Hagen, Jaqueline Rauh, Helge Schröder, Peter Jaehnig, Karin Potthoff, Christian Lerchenmüller
Adult weight gain accelerates the onset of breast cancer
Maria Azrad, Cindy K. Blair, Cheryl L. Rock, Rebecca L. Sedjo, Kathleen Y. Wolin, Wendy Demark-Wahnefried
Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis
Mira Goldberg, Rinku Sutradhar, Lawrence Paszat, Timothy J. Whelan, Sumei Gu, Cindy Fong, Eileen Rakovitch
Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer
Yun Rose Li, Vicky Ro, Laura Steel, Elena Carrigan, Jenny Nguyen, Austin Williams, Alycia So, Julia Tchou
Effects of tea consumption and the interactions with lipids on breast cancer survival
Jia-Yi Zhang, Yu-Huang Liao, Ying Lin, Qiang Liu, Xiao-Ming Xie, Lu-Ying Tang, Ze-Fang Ren
Breast cancer risk in relation to plasma metabolites among Hispanic and African American women
Hua Zhao, Jie Shen, Steven C. Moore, Yuanqing Ye, Xifeng Wu, Francisco J. Esteva, Debasish Tripathy, Wong-Ho Chow
Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women
Hua Zhao, Jie Shen, Steven C. Moore, Yuanqing Ye, Xifeng Wu, Francisco J. Esteva, Debasish Tripathy, Wong-Ho Chow
Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy
Lynn Jongen, Giuseppe Floris, Hans Wildiers, Frank Claessens, François Richard, Annouschka Laenen, Christine Desmedt, Jan Ardui, Kevin Punie, Ann Smeets, Patrick Berteloot, Ignace Vergote, Patrick Neven
Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy
Zahraa Al-Hilli, Grace Choong, Michael G. Keeney, Daniel W. Visscher, James N. Ingle, Matthew P. Goetz, James W. Jakub
Microinvasion: could it be sufficient diagnostic criteria for the optimal treatment decision?
Darko Zdravkovic, Nebojsa Ivanovic, Bogdan Crnokrak
HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features
Kadri Altundag